CHLOROMYCETIN (chloramphenicol) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1951.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CHLOROMYCETIN (chloramphenicol) is a broad-spectrum bacteriostatic antibiotic originally isolated from Streptomyces venezuelae, approved in 1951 for ophthalmic use. It treats surface ocular infections of the conjunctiva and cornea by inhibiting bacterial protein synthesis through interference with amino acid transfer to ribosomes. The drug is formulated as an ophthalmic ointment with minimal resistance development in susceptible organisms.
With LOE approaching and no Part D spending data, the ophthalmic franchise is likely managed by a lean, specialized team focused on legacy product maintenance rather than growth expansion.
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CHLOROMYCETIN offers minimal career growth opportunity as a legacy ophthalmic antibiotic in LOE stage with no linked jobs and zero clinical pipeline activity. This role suits professionals managing mature portfolios or transitioning toward regulatory/compliance specialization, but does not provide exposure to innovation, market expansion, or leadership development.